Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCR-300
- Development stage
- Phase 1
- Lead developer
- Nuwacell Biotechnologies
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intraperitoneal
01
Overview
NCR-300 is a cell therapy product composed of natural killer (NK) cells, under clinical development by Nuwacell Biotechnology. It is being investigated for the treatment of several cancers, including high grade ovarian serous carcinoma, endometrioid carcinoma, primary peritoneal carcinoma, acute myeloid leukemia (AML), fallopian tube carcinoma, and myelodysplastic syndrome. The drug is administered intravenously or intraperitoneally. Its mechanism of action involves immunologic cytotoxicity as a natural killer cell replacement therapy[1][2][4].
- Other names
- iNK cellsiPSC-derived natural killer cellshuman induced pluripotent stem cell derived natural killer cellsiNK Injection
02
Targets
NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on NCR-300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCR-300.